The latest report by IMARC, titled “Breast Cancer Liquid Biopsy Market Report by Product Services (Reagent Kits, Instruments, Services), Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Others), End User (Reference Laboratories, Hospitals and Physician Laboratories, and Others), and Region 2024-2032”, finds that the global breast cancer liquid biopsy market size reached US$ 130.4 Million in 2023. Breast cancer liquid biopsy refers to a non-invasive medical process that uses blood as a sample for the recognition of tumor markers. It helps in evaluating the progression of breast cancer disease and detects Epidermal Growth Factor Receptor (EGFR) gene mutations that assist health professionals in choosing the best course of treatment at the appropriate time. Some of the most commonly used biomarkers include extracellular vesicles, circulating tumor cells (CTC), circulating tumor DNA, and others. In recent years, breast cancer liquid biopsy has gained traction as it offers numerous advantages, such as the characterization of new lesions, minimal invasiveness, drug and therapeutic target identifications for cancer treatment.
Global Breast Cancer Liquid Biopsy Market Trends:
One of the primary factors driving the market is the increasing number of individuals diagnosed with breast cancer. Additionally, breast cancer liquid biopsy offers multiple benefits, such as quicker results, minimal health risk, lower cost, non-invasiveness, and others, thereby creating a positive market outlook. Other than this, the surging demand for pre-screening programs for breast cancer detection, along with easy accessibility and extensive utilization of polymerase chain reaction (PCR) and next-generation sequencing (NGS) among clinical, is positively influencing the market growth. Besides this, numerous global organizations are conducting awareness campaigns in order to educate individuals about breast health and cancer diagnostic measures. In line with this, governments of numerous nations are offering reimbursement policies for breast cancer biopsy and other related medical procedures, consequently propelling market growth. Furthermore, key players are extensively investing in the introduction of advanced biopsy techniques that improve several aspects of breast cancer management, including early diagnosis of relapse, efficient longitudinal monitoring of diseases progress and response to treatment, and others. Looking forward, IMARC Group expects the market value to reach US$ 497.2 Million by 2032, expanding at a CAGR of 15.5% during the forecast period (2024-2032).
Market Summary:
- Based on the product services, the market has been divided into reagent kits, instruments, and services.
- On the basis of the circulating biomarker, the market has been segregated into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vehicles (EVs), and others.
- Based on the end user, the market has been segmented into reference laboratories, hospitals and physician laboratories, and others.
- Region-wise, the market has been classified into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
- The competitive landscape of the market has also been analyzed, with some of the key players being Biocept Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Menarini Silicon Biosystems (The Menarini Group), NeoGenomics Laboratories Inc., Qiagen, and Sysmex Europe SE (Sysmex Corporation).
Report Scope:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Million |
Segment Coverage |
Product Services, Circulating Biomarker, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Biocept Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Menarini Silicon Biosystems (The Menarini Group), NeoGenomics Laboratories Inc., Qiagen and Sysmex Europe SE (Sysmex Corporation) |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800